Technical Appendix Table.

Costs and epidemiologic parameters related to chlamydia testing and treatment for the U.S. safety net population aged 15–44 years, 2013–2023

^aAll costs were adjusted using the Medical Care component of the Consumer Price Index because of symptoms or because of repeat testing following a previous chlamydia diagnosis. Source: Health Resources and Services Administration (US), Bureau of Labor Statistics. Consumer price index [cited 2015 Apr 20]. Available from: URL: http://www.bls.gov/cpi

^bGift TL, Gaydos CA, Kent CK, Marrazzo JM, Rietmeijer CA, Schillinger JA, et al. The program cost and cost-effectiveness of screening men for chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis 2008;35(11 Suppl):S66-75.

^cTreatment cost was applied to patients diagnosed as a result of screening.

^dTreatment and follow-up visit costs were applied to patients who were infected with chlamydia and who sought evaluation.

^eOwusu-Edusei K Jr, Doshi SR, Apt BS, Gift TL. The direct cost of chlamydial infections: estimates for the employer-sponsored privately insured population in the United States, 2003–2007 [published erratum appears in Sex Transm Dis 2011;38:888]. Sex Transm Dis 2010;37:519-21.

^fSatterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among U.S. women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013;40:187-93.

^gHosenfeld CB, Workowski KA, Berman S, Zaidi A, Dyson J, Mosure D, et al. Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009;36:478-89.

^hFung M, Scott KC, Kent CK, Klausner JD. Chlamydia and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect 2007;83:304-9.